Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 443 Show results per page	View Search Criteria \| Help With Results


1.		PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				20050100 NCT00352703


2.		Phase II-III Chemotherapy with Peptichemio vs Melphalan in Refractory Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								MDA-MBDT-7814


3.		Phase II-III Chemotherapy with Hexamethylmelamine and L-Phenylalanine Mustard for Stage III and IV Ovarian Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								DFCI-75118

Last Modified: 11/1/1988


4.		Phase II/III Multimodality Therapy with Surgery, CTX/ADR/5-FU/TMX/FLU, plus Radiotherapy for Stage III Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 69								WCCC-CO-8111 NCI-D81-048-515

Last Modified: 12/1/1989


5.		Phase II/III L-PAM/PRED/VCR vs VP-16/PRED/ADR for Stage II/III Myeloma (Summary Last Modified 12/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				20 and over								SAFR-CT-MM-2


6.		Chemotherapy with 5-FU, Streptozotocin, Spironolactone and L-PAM for Advanced Nonmeasurable Pancreatic Carcinoma (Summary last modified 06/97 ko)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-5274 MAYO-706031

Last Modified: 11/26/2007


7.		Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				0 to 18				NCI				CCG-3891 CCG-3891

Last Modified: 12/6/2007 First Published: 9/24/2003


8.		Phase II/III Randomized Study of Immunotherapy Comprising Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				Under 30				NCI				COG-AHOD0121 NCT00070187, AHOD0121

Last Modified: 5/4/2007 First Published: 1/1/1994


9.		NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Study of Melphalan/Total Body Irradiation with Peripheral Blood Stem Cell Rescue vs VBMCP (Vincristine/Carmustine/Melphalan/Cyclophosphamide/Prednisone) Following Standard Induction for Previously Untreated Symptomatic Multiple Myeloma, with Further Randomization for Major Responders to Interferon alfa vs Observation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				70 and under				NCI				SWOG-9321 CLB-9312, E-S9321, INT-0141, NCT00002548

Last Modified: 11/30/2007 First Published: 4/1/1994


10.		Phase III Randomized Study of Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone (VBMCP) Alone Versus VBMCP Alternating First With High-Dose Cyclophosphamide and Then With Interferon alfa in Patients With Previously Untreated Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-5A93 NCT00002556, E5A93

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute